홈 › 급성 골수성 백혈병 › 유타
유타의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 17개가 유타 내 여러 지역에서 참여자를 모집하고 있습니다.
유타의 도시
공식 연구 텍스트(영어)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Intermountain Healthcare LDS Hospital, Salt Lake City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
- George E Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Primary Children's Hospital, Salt Lake City
피험자 모집 중3상
6 Months – 21 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT06824168(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04996875A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중1상
18세 ~ 75세 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Primary Children's Hospital, Salt Lake City
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Primary Children's Hospital, Salt Lake City
피험자 모집 중3상
29 Days – 21 Years · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT05183035A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Utah, Salt Lake City
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545Ivosidenib as Post-HSCT Maintenance for AML
- Huntsman Cancer Institute, University of Utah, Salt Lake City
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 6. 18. 업데이트됨 · NCT06707493Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Utah, Salt Lake City
피험자 모집 중1상
13세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04771572Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- University of Utah, Salt Lake City
피험자 모집 중1상
21세 이하 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT05101551A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.